|
ADA
Jan 31, 2018 10:52:12 GMT -5
Post by agedhippie on Jan 31, 2018 10:52:12 GMT -5
Well, it sure looks like Amazon is not waiting for trials. ... Diabetes is a HUGE expense. Amazon isn't waiting for trials because it's not changing the standard of care. This is about cutting out the middle man to reduce costs to the business. Drugs will still be prescribed by doctors, not insurers, and doctors follow the standard of care. That's all you need to know. That diabetes is a huge expense will come as a surprise to nobody. These companies self-insure today so they know what that bill looks like. Equally they could get Afrezza put into their plans tomorrow with just a phone call but it has not happened. Simply removing the insurer from the picture as is being proposed does not change that decision.
|
|
|
Post by mnholdem on Feb 14, 2018 19:16:21 GMT -5
Dr. Kendall joining MannKind changes the complexion of the STAT presentation tremendously, IMO, assuming that David will be the MannKind executive who will presenting the results of the STAT study. Kendall has the popularity to draw a standing room only crowd and I would hope that he will be working with the ADA to schedule to best time for his presentation at the 2018 ADA Scientific Sessions.
|
|
|
Post by peppy on Feb 14, 2018 19:32:11 GMT -5
Dr. Kendall joining MannKind changes the complexion of the STAT presentation tremendously, IMO, assuming that David will be the MannKind executive who will presenting the results of the STAT study. Kendall has the popularity to draw a standing room only crowd and I would hope that he will be working with the ADA to schedule to best time for his presentation at the 2018 ADA Scientific Sessions. it is going to be standing room only, when the Continuous glucose monitor results get posted. physicians are not stupid, they can see. let's see what the physicians do after the results.
|
|
|
Post by centralcoastinvestor on Feb 14, 2018 19:41:26 GMT -5
Dr. Kendall joining MannKind changes the complexion of the STAT presentation tremendously, IMO, assuming that David will be the MannKind executive who will presenting the results of the STAT study. Kendall has the popularity to draw a standing room only crowd and I would hope that he will be working with the ADA to schedule to best time for his presentation at the 2018 ADA Scientific Sessions. People ask why Dr. Kendall switched from a good job to come to MannKind. I think he really wants to change the diabetes treatment paradigm. And that is very good thing for MannKind and Afrezza.
|
|
|
Post by celo on Feb 14, 2018 19:41:39 GMT -5
Dr. Kendall joining MannKind changes the complexion of the STAT presentation tremendously, IMO, assuming that David will be the MannKind executive who will presenting the results of the STAT study. Kendall has the popularity to draw a standing room only crowd and I would hope that he will be working with the ADA to schedule to best time for his presentation at the 2018 ADA Scientific Sessions. it is going to be standing room only, when the Continuous glucose monitor results get posted. physicians are not stupid, they can see. let's see what the physicians do after the results. Let's hope the doctors go to the insurers and tell them to wake the hell up.
|
|
|
Post by dreamboatcruise on Feb 14, 2018 19:55:01 GMT -5
Dr. Kendall joining MannKind changes the complexion of the STAT presentation tremendously, IMO, assuming that David will be the MannKind executive who will presenting the results of the STAT study. Kendall has the popularity to draw a standing room only crowd and I would hope that he will be working with the ADA to schedule to best time for his presentation at the 2018 ADA Scientific Sessions. I would think it would be the University CO principal investigator that would be presenting.
|
|
|
Post by sayhey24 on Feb 14, 2018 20:00:14 GMT -5
Big Dave is going to be too busy meeting with BP & Mike and telling Mike, not enough.
|
|
|
Post by akemp3000 on Feb 14, 2018 20:05:26 GMT -5
I agree it will likely be presented by the University of Colorado. Hopefully, Dr. Kendall can at least be on stage to help drive attendance and answer questions...and there will be two GIANT CGMs overhead lighting up like scoreboards to show the results. Ok...I know this won't happen at the ADA but it would be awesome and memorable.
|
|
|
Post by xanet on Feb 14, 2018 20:13:43 GMT -5
I agree it will likely be presented by the University of Colorado. Hopefully, Dr. Kendall can at least be on stage to help drive attendance and answer questions...and there will be two GIANT CGMs overhead lighting up like scoreboards to show the results. Ok...I know this won't happen at the ADA but it would be awesome and memorable. Don't you think that would give the appearance that the study was biased? All that aside, I do like your enthusiasm and also hope for good things sooner rather than later. This has been a long road, and I would like to see this life-returning product succeed!
|
|
|
Post by akemp3000 on Feb 14, 2018 20:22:50 GMT -5
I agree it will likely be presented by the University of Colorado. Hopefully, Dr. Kendall can at least be on stage to help drive attendance and answer questions...and there will be two GIANT CGMs overhead lighting up like scoreboards to show the results. Ok...I know this won't happen at the ADA but it would be awesome and memorable. Don't you think that would give the appearance that the study was biased? All that aside, I do like your enthusiasm and also hope for good things sooner rather than later. This has been a long road, and I would like to see this life-returning product succeed! The study was completed before Dr. Kendall joined Mannkind but I do agree it wouldn't look good to have only one drug company represented on stage. Maybe Dr. Kendall can just walk up to accept the winner's trophy...with "We Are The Champions" playing in the background
|
|
|
Post by xanet on Feb 14, 2018 20:49:02 GMT -5
Not sure if anyone posted this elsewhere, but the preliminary program is out: www.nxtbook.com/nxtbooks/ada/scientificsessions2018_advance/index.php#/1There are some interesting topics, such as "Should Metformin Remain the First Line Therapy for Type 2 Diabetes?" I didn't see the STAT study anywhere obvious, but I don't think the Oral Presentations are included in this preliminary program.
|
|
|
ADA
Feb 14, 2018 21:16:29 GMT -5
xanet likes this
Post by dreamboatcruise on Feb 14, 2018 21:16:29 GMT -5
Not sure if anyone posted this elsewhere, but the preliminary program is out: www.nxtbook.com/nxtbooks/ada/scientificsessions2018_advance/index.php#/1There are some interesting topics, such as "Should Metformin Remain the First Line Therapy for Type 2 Diabetes?" I didn't see the STAT study anywhere obvious, but I don't think the Oral Presentations are included in this preliminary program. And "Clinical strategies for Prevention and Management of Hypoglycemia"
|
|
|
Post by kc on Feb 14, 2018 21:39:09 GMT -5
I agree it will likely be presented by the University of Colorado. Hopefully, Dr. Kendall can at least be on stage to help drive attendance and answer questions...and there will be two GIANT CGMs overhead lighting up like scoreboards to show the results. Ok...I know this won't happen at the ADA but it would be awesome and memorable. MannKind can also sponsor some presentation room discussions. Sanofi did that the one year they had Afrezza’s coming out party.
|
|
|
ADA
Feb 15, 2018 12:21:51 GMT -5
nylefty likes this
Post by agedhippie on Feb 15, 2018 12:21:51 GMT -5
Not sure if anyone posted this elsewhere, but the preliminary program is out: www.nxtbook.com/nxtbooks/ada/scientificsessions2018_advance/index.php#/1There are some interesting topics, such as "Should Metformin Remain the First Line Therapy for Type 2 Diabetes?" I didn't see the STAT study anywhere obvious, but I don't think the Oral Presentations are included in this preliminary program. My bet is that the paper is a cage fight between the GLP-1 and metformin teams. There has been an ongoing debate about this topic on this over the last year (DeFronzo for GLP-1, and Inzucchi for metformin) played out in Diabetes Care.
|
|
|
Post by sayhey24 on Feb 15, 2018 15:24:17 GMT -5
I would say you are correct but I find it interesting that "Mr. Metformin" has jumped ship and is ready to dump metformin. I heard him say it last year but WOW! I say good for him but it starts with do no harm and the GLP-1s have some real scary side effects.
Now, if its really DeFronzo wanting to dump metformin that opens the door wide open to Kendall and his afrezza. Head to head afrezza is safer and will provide better results.
|
|